Intensifying Chemotherapy with Rituxan of Little Help to Advanced Hodgkins Lymphoma Patients, HD18 Trial Shows
News
Intensifying standard chemotherapy, known as escalated eBEACOPP, with the anti-CD20 antibody Rituxan (rituximab) showed no added benefit to progression-free survival in patients with advanced-stage Hodgkin’s lymphoma (HL), according to updated results ... Read more